Medimmune Limited

Zenyth Operations Pty. Ltd.

Elan Pharma International Limited

Matthew Alexander Sleeman

David C Lowe

Emma Suzanne Cohen

Darren Schofield

Jonathan P Hatcher

Iain Patrick Chessell

Ralph Raymond Minter

Andrew Donald Nash

Louis Jerry Fabri

Fraser Welsh

Paula Rosamund Harrison

Andrew Grier Buchanan

Philip Bland-Ward

Sara Carmen

Albert George Thom

Katherine Ann Vousden

Jon Eric Hawkinson

Ruth Franks

Tomas M Mustelin

David G Rees

Elizabeth H England

Carl Anthony Matthews

Celia Patricia Hart

Benjamin P Kemp

Robin Butler

Catherine L Overed-Sayer

Ian C Scott

Kirsty Houslay

Martin D Strain

Caroline S Russell

Duncan James Cochrane

Caroline Langham

Maurice Needham

Patrick Dufner

Jonathan Hatcher

David Lowe

Fraser Ewing Welsh

Philip Antony Bland-Ward

Jon Hawkinson

Paula Harrison

Louis Fabri

Caroline Russell

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNFα antagonist. The NGF antagonist and the TNFα antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNFα antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNFα antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNFα antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNFα antagonist administered alone.

Compounds and methods for treating pain

The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.

Polynucleotides encoding IL33 antibodies and methods of using the same

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF&#x3b1; antagonist. The NGF antagonist and the TNF&#x3b1; antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF&#x3b1; antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF&#x3b1; antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF&#x3b1; antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF&#x3b1; antagonist administered alone.

IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same

Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.

Methods of treating neuropathic pain with specific binding members for NGF

Specific binding members for NGF

Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR&#x3b1;), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.

Antibody molecule for human GM-CSF receptor alpha

Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.

Antibodies to IL-17A and uses thereof

Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR&#x3b1;), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.

Growing community of inventors

Cambridgeshire, United Kingdom

Matthew Alexander Sleeman